Yes, what IF we "only" delivered a 15% improvement or a 18% improvement or a 23% improvement - I'd imagine we'd be selling all the product we could make - what if we "only" delivered a "modest" improvement to the long-term functioning of the heart, liver, kidneys, lungs etc etc etc.....these would be very rewarding "only" outcomes and we likely are right in that space - we need to know more ASAP please.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-337
-
- There are more pages in this discussion • 739 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
0.020(2.11%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 94.5¢ | 98.0¢ | 93.5¢ | $3.680M | 3.810M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 149921 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |